Natera, INC Form 4 insider transactions

Natera, Inc. director Roelof Botha acquired 354 shares of common stock through the issuance of restricted stock units as part of board compensation.

Natera, Inc. Director Eric H. Rubin acquired 5 shares of common stock via restricted stock units in lieu of quarterly retainer fees.

Director Brinkley Ruth Williams acquired 86 shares of Natera, Inc. common stock via restricted stock units in lieu of cash retainer fees.

Director Monica Bertagnolli acquired 83 shares of Natera, Inc. common stock via fully vested restricted stock units in lieu of cash retainer fees.

Director Roy D. Baynes acquired 83 shares of Natera, Inc. common stock via fully vested Restricted Stock Units in lieu of quarterly retainer fees.

Natera Director and Co-Founder Jonathan Sheena sold 1,500 shares of common stock through trust accounts under a pre-arranged trading plan.

Natera, Inc. Executive Chairman Matthew Rabinowitz reported transactions involving the sale of company stock.

Natera, Inc. reports that its Chief Legal Officer, Daniel Rabinowitz, sold a significant number of common shares through a pre-arranged trading plan.

Natera, Inc. President of Clinical Diagnostics, Solomon Moshkevich, has sold a total of 3,000 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Matthew Rabinowitz, Executive Chairman of Natera, Inc., exercised 41,708 stock options at $9.59 per share.

Natera Co-Founder Jonathan Sheena executed pre-scheduled sales of common stock totaling 4,570 shares across multiple transactions in March 2026.

Natera Director Rowan E. Chapman sold 122 shares of common stock for $191.38 per share under a pre-arranged 10b5-1 trading plan.

Natera's Executive Chairman, Matthew Rabinowitz, exercised stock options and subsequently sold a significant number of common shares under a pre-arranged Rule 10b5-1 trading plan.

Natera's Chief Financial Officer, Michael Burkes Brophy, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Natera CEO Steven Leonard Chapman sold 5,623 shares of common stock to cover tax obligations related to vested Restricted Stock Units.

Natera's SEC and Chief Legal Officer, Daniel Rabinowitz, reported the acquisition and subsequent sale of company common stock to cover tax obligations related to RSU vesting.

Natera Co-Founder and Director Jonathan Sheena reported the vesting of Restricted Stock Units and a subsequent sale of shares to cover tax obligations.

Natera's President and Chief Business Officer, John Fesko, reported the acquisition of vested restricted stock units and subsequent sale of shares for tax obligations.

Natera's Co-Founder and Director, Jonathan Sheena, reported the acquisition of Restricted Stock Units and subsequent sales of common stock under a pre-arranged trading plan.

Natera CEO Steven Leonard Chapman reported the grant of 37,401 Restricted Stock Units and subsequent sales of 3,950 shares of common stock under a pre-arranged 10b5-1 trading plan.

Natera's President of Clinical Diagnostics, Solomon Moshkevich, increased his beneficial ownership through RSU grants and option exercises, while also selling a portion of shares under a pre-arranged trading plan.

Matthew Rabinowitz, Natera's Executive Chairman, was granted 29,920 Restricted Stock Units with a four-year vesting schedule.

Natera's SEC and Chief Legal Officer, Daniel Rabinowitz, was granted 12,272 Restricted Stock Units, increasing his beneficial ownership to 236,085 shares.

Natera's President and Chief Business Officer, John Fesko, was granted 10,051 Restricted Stock Units, aligning his interests with shareholders.

Natera, Inc.'s Chief Financial Officer, Michael Burkes Brophy, was granted 10,051 Restricted Stock Units, increasing his direct beneficial ownership to 62,171 shares.

Natera's President of Clinical Diagnostics, Solomon Moshkevich, reported the sale of 4,639 common shares through pre-arranged trading plans.

Natera CEO and President Steven Leonard Chapman sold 89,024 shares of common stock in early February 2026, primarily under a pre-arranged 10b5-1 trading plan.

Natera's Chief Financial Officer, Michael Burkes Brophy, sold 6,939 shares of common stock for tax obligations and under a pre-arranged trading plan.

Natera's President and Chief Business Officer, John Fesko, sold shares of common stock to cover tax obligations related to RSU vesting.

Jonathan Sheena, Natera's Co-Founder and Director, sold 435 shares of common stock to cover tax obligations related to RSU vesting.